OBJECTIVE: Most youth with type 1 diabetes do not meet the American Diabetes Association (ADA) and International Society for Pediatric and Adolescent Diabetes (ISPAD) targets for hemoglobin A1c (HbA1c), blood pressure (BP), lipids, and body mass index (BMI). We hypothesized that ISPAD/ADA goal achievement at baseline would be associated with cardiorenal risk factors at baseline and 2 yr follow-up in adolescents with type 1 diabetes. METHODS: We assessed the cross-sectional and longitudinal relationships between ISPAD/ADA goal achievement at baseline and cardiorenal health at baseline and 2-yr follow-up (n = 297; 15.4 ± 2.1 yr at baseline) in adolescents with type 1 diabetes. Goal achievement was defined as HbA1c < 7.5%, BP < 90th percentile for age, sex, and height, low density lipoprotein-cholesterol (LDL-C) <100 mg/dL, high density lipoprotein-cholesterol (HDL-C) >35 mg/dL, triglycerides (TG) <150 mg/dL and BMI <85th percentile for age and sex. Cardiorenal outcomes included pulse-wave velocity (PWV), brachial distensibility (BrachD), augmentation index (AIx), and epidermal growth factor receptor (eGFR) continuously and categorically as hyperfiltration (eGFR ≥ 135 mL/min/1.73 m(2)). RESULTS: Adolescents with type 1 diabetes who met 1-3 goals, had significantly greater (P < 0.05) baseline PWV (5.1 ± 0.1 vs. 5.4 ± 0.1 m/s), follow-up PWV (5.5 ± 0.1 vs. 5.7 ± 0.1 m/s), greater follow-up eGFR (104 ± 2 vs. 116 ± 3 mL/min/1.73 m(2)), and greater odds of renal hyperfiltration at follow-up (odds ratio (OR): 20.0, 95% confidence interval (CI): 3.8-105.2) compared to those who met 4-6 goals after adjusting for Tanner stage, sex, age, and diabetes duration. No statistically significant differences in the cardiorenal outcomes were observed between adolescents with type 1 diabetes who met 4-6 goals and non-diabetic controls (n = 96). CONCLUSIONS: In adolescents with type 1 diabetes, baseline ADA/ISPAD goal achievement was associated with cardiorenal protection at baseline and 2-yr follow-up.
OBJECTIVE: Most youth with type 1 diabetes do not meet the American Diabetes Association (ADA) and International Society for Pediatric and Adolescent Diabetes (ISPAD) targets for hemoglobin A1c (HbA1c), blood pressure (BP), lipids, and body mass index (BMI). We hypothesized that ISPAD/ADA goal achievement at baseline would be associated with cardiorenal risk factors at baseline and 2 yr follow-up in adolescents with type 1 diabetes. METHODS: We assessed the cross-sectional and longitudinal relationships between ISPAD/ADA goal achievement at baseline and cardiorenal health at baseline and 2-yr follow-up (n = 297; 15.4 ± 2.1 yr at baseline) in adolescents with type 1 diabetes. Goal achievement was defined as HbA1c < 7.5%, BP < 90th percentile for age, sex, and height, low density lipoprotein-cholesterol (LDL-C) <100 mg/dL, high density lipoprotein-cholesterol (HDL-C) >35 mg/dL, triglycerides (TG) <150 mg/dL and BMI <85th percentile for age and sex. Cardiorenal outcomes included pulse-wave velocity (PWV), brachial distensibility (BrachD), augmentation index (AIx), and epidermal growth factor receptor (eGFR) continuously and categorically as hyperfiltration (eGFR ≥ 135 mL/min/1.73 m(2)). RESULTS: Adolescents with type 1 diabetes who met 1-3 goals, had significantly greater (P < 0.05) baseline PWV (5.1 ± 0.1 vs. 5.4 ± 0.1 m/s), follow-up PWV (5.5 ± 0.1 vs. 5.7 ± 0.1 m/s), greater follow-up eGFR (104 ± 2 vs. 116 ± 3 mL/min/1.73 m(2)), and greater odds of renal hyperfiltration at follow-up (odds ratio (OR): 20.0, 95% confidence interval (CI): 3.8-105.2) compared to those who met 4-6 goals after adjusting for Tanner stage, sex, age, and diabetes duration. No statistically significant differences in the cardiorenal outcomes were observed between adolescents with type 1 diabetes who met 4-6 goals and non-diabetic controls (n = 96). CONCLUSIONS: In adolescents with type 1 diabetes, baseline ADA/ISPAD goal achievement was associated with cardiorenal protection at baseline and 2-yr follow-up.
Authors: Allan J Collins; Robert N Foley; Charles Herzog; Blanche Chavers; David Gilbertson; Areef Ishani; Bertram Kasiske; Jiannong Liu; Lih-Wen Mau; Marshall McBean; Anne Murray; Wendy St Peter; Haifeng Guo; Sally Gustafson; Qi Li; Shuling Li; Suying Li; Yi Peng; Yang Qiu; Tricia Roberts; Melissa Skeans; Jon Snyder; Craig Solid; Changchun Wang; Eric Weinhandl; David Zaun; Cheryl Arko; Shu-Cheng Chen; Frederick Dalleska; Frank Daniels; Stephan Dunning; James Ebben; Eric Frazier; Christopher Hanzlik; Roger Johnson; Daniel Sheets; Xinyue Wang; Beth Forrest; Edward Constantini; Susan Everson; Paul Eggers; Lawrence Agodoa Journal: Am J Kidney Dis Date: 2011-01 Impact factor: 8.860
Authors: Janet Silverstein; Georgeanna Klingensmith; Kenneth Copeland; Leslie Plotnick; Francine Kaufman; Lori Laffel; Larry Deeb; Margaret Grey; Barbara Anderson; Lea Ann Holzmeister; Nathaniel Clark Journal: Diabetes Care Date: 2005-01 Impact factor: 19.112
Authors: Petter Bjornstad; David M Maahs; Marian Rewers; Richard J Johnson; Janet K Snell-Bergeon Journal: J Diabetes Complications Date: 2014-07-04 Impact factor: 2.852
Authors: K Otfried Schwab; Jürgen Doerfer; Wolfgang Hecker; Jürgen Grulich-Henn; Dagobert Wiemann; Olga Kordonouri; Peter Beyer; Reinhard W Holl Journal: Diabetes Care Date: 2006-02 Impact factor: 19.112
Authors: A S Krolewski; E J Kosinski; J H Warram; O S Leland; E J Busick; A C Asmal; L I Rand; A R Christlieb; R F Bradley; C R Kahn Journal: Am J Cardiol Date: 1987-04-01 Impact factor: 2.778
Authors: Sarah Stark Casagrande; Judith E Fradkin; Sharon H Saydah; Keith F Rust; Catherine C Cowie Journal: Diabetes Care Date: 2013-02-15 Impact factor: 19.112
Authors: Petter Bjornstad; Melanie Cree-Green; Amy Baumgartner; Gregory Coe; Yesenia Garcia Reyes; Michal Schafer; Laura Pyle; Judith G Regensteiner; Jane E B Reusch; Kristen J Nadeau Journal: J Diabetes Complications Date: 2017-03-14 Impact factor: 2.852
Authors: Pattara Wiromrat; Petter Bjornstad; Carissa Vinovskis; Linh T Chung; Carlos Roncal; Laura Pyle; Miguel A Lanaspa; Richard J Johnson; David Z Cherney; Tyler K Reznick-Lipina; Franziska Bishop; David M Maahs; Raj Paul Wadwa Journal: Pediatr Diabetes Date: 2019-08-29 Impact factor: 4.866
Authors: Pattara Wiromrat; Petter Bjornstad; Carlos Roncal; Laura Pyle; Richard J Johnson; David Z Cherney; Tyler Lipina; Franziska Bishop; David M Maahs; R Paul Wadwa Journal: J Diabetes Complications Date: 2019-06-03 Impact factor: 2.852
Authors: Petter Bjornstad; Carlos Roncal; Tamara Milagres; Laura Pyle; Miguel Angel Lanaspa; Franziska K Bishop; Janet K Snell-Bergeon; Richard J Johnson; R Paul Wadwa; David M Maahs Journal: Pediatr Nephrol Date: 2015-12-23 Impact factor: 3.714